Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

PHASE2TerminatedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 2, 2017

Study Completion Date

November 2, 2017

Conditions
Mild Cognitive Impairment
Interventions
DRUG

[18F]NAV4694

Trial Locations (11)

10461

Albert Einstein College of Medicine, The Bronx

12208

Neurological Associates of Albany, Albany

21157

Wake Forest School of Medicine, Winston-Salem

32806

Compass Research, Orlando

33016

Galiz Research, Hialeah

33140

Mt. Sinai Wien Center for Alzheimer's Disease, Miami Beach

60612

Rush University Medical Center, Chicago

62702

SIU School of Medicine, Springfield

85351

Banner Sun Health Research Institute, Sun City

02478

McLean Hospital, Belmont

02169

Qunicy Medical Center, Alzheimer's Disease Center, Quincy

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY